Intellikine

Intellikine is focused on the R&D of orally available small molecule drugs targeting the PI3K/mTOR pathway.

Intellikine works in the discovery and development of novel, small molecule therapies targeting the PI3K/Akt/mTOR pathway. Intellikine is committed to building an exceptional team and a powerful discovery platform that rapidly generates small molecule kinase inhibitor drug candidates that will become the next generation of medical breakthroughs.